Skip to content

Copeptin in Differentiation of Polyuria and Polydipsia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01056887
Enrollment
50
Registered
2010-01-26
Start date
2008-03-31
Completion date
2010-11-30
Last updated
2011-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polydipsia, Polyuria

Keywords

diabetes insipidus, primary polydipsia, copeptin, Utility of plasma copeptin in differential diagnosis of polyuria/ polydipsia while performing a traditional deprivation test

Brief summary

The differential diagnosis of patients with polyuria/ polydipsia is often complex, but important for the therapeutic strategy. Challenging is in particular the clinical differentiation between patients with a partial Diabetes insipidus centralis and patients with primary polydipsia as underlying disease, because both groups are associated with similar urinary osmolalities. The determination of plasma arginine vasopressin is unusual in this context, since measurement of AVP is not reliably. C-terminal ProVasopressin (copeptin) is secreted stoichiometrically with AVP from the neurohypophysis, but has a longer half life in the circulation, and is thus easier to measure. Therefore, the investigators will analyze in that study the diagnostic utility of plasma copeptin in the differential diagnosis of polyuria and polydipsia.

Interventions

None listed

Sponsors

Dr. Carson Liu Med Corp.
CollaboratorINDUSTRY
University of Wuerzburg
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients with polydipsia/ polyuria, with indication for performing a deprivation test * \> 18 years

Exclusion criteria

* dDAVP during the last 14d * pregnancy

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026